S100A7 promotes the migration and invasion of osteosarcoma cells via the receptor for advanced glycation end products

Abstract

Osteosarcoma is the most common malignant tumor of bone in childhood and adolescence. Despite intensive research for new therapies, the outcome in patients with metastasis remains extremely poor. S100 proteins are involved in the proliferation, cell cycle progression and metastasis of numerous malignant tumors, including osteosarcoma. In the present study, we identified S100A7 as a candidate to promote the migration of osteosarcoma cells. S100A7 promoted the migration and invasion of osteosarcoma cells as assayed in vitro. An in vitro pull-down assay revealed the binding of the recombinant S100A7 protein with its putative receptor, the receptor for advanced glycation end products (RAGE). The downregulation of RAGE by a specific siRNA markedly suppressed the migration and invasion of osteosarcoma cells. Furthermore, the matrix metalloproteinase activity of osteosarcoma cells was enhanced by S100A7 and suppressed by the downregulation of RAGE. These results indicate that S100A7 promotes the migration and invasion of osteosarcoma cells through RAGE. The S100A7-RAGE axis may thus be a new target for preventing the invasion and/or metastasis of osteosarcoma.

Introduction

Osteosarcoma is the most common malignant tumor of bone in childhood and adolescence (1). It is an aggressive tumor that metastasizes primarily to the lung. Clinical efforts, including the development of protocols for effective chemotherapy, have significantly improved the 5-year survival rate of osteosarcoma patients from 15 to 70% (2). However, 30-40% of patients still succumb to the disease, mainly due to distant metastasis to the lung (3). Despite intensive research for new therapies, the outcome in patients with metastasis remains extremely poor.

The S100 protein family consists of 20 calcium-binding proteins with EF hand motifs (4). S100 proteins have been shown to have intracellular and extracellular roles in the regulation of diverse processes, including protein phosphorylation, cell growth and motility, cell-cycle regulation, transcription, differentiation and cell survival (5). S100 proteins are normally expressed in a tissue-specific manner and their dysregulation has been causally linked to numerous diseases, including several types of cancer (6). For example, S100A4 is involved in proliferation, cell cycle progression and the metastasis of a number of malignant tumors, including osteosarcoma (7). In a screening study for S100 proteins potentially involved in the migration of osteosarcoma cells, we identified S100A7 as a candidate.

S100A7 (Psoriasin) was originally identified as a protein that is upregulated in psoriatic skin (8). Several S100 proteins, including S100A7, S100A8/9, S100A12 and S100A15 (koebnerisin) were found to be upregulated in psoriatic skin (4,9) and these S100 proteins are localized within the epidermal differentiation complex (EDC) on human chromosome 1 (1q21) (10). Among the S100 family genes in the EDC, S100A7 and S100A15 are almost identical in sequence (<90%). Despite their similarity, S100A7 and S100A15 are distinct in tissue distribution, regulation and function, being exemplary for the diversity within the S100 family (9). In skin tissue, S100A7 interacts with epidermal fatty acid-binding protein and the expression of S100A7 is elevated under pathological conditions, including inflammation and hyperproliferation (4). Wolf et al reported that S100A7 acts through its putative receptor, the receptor for advanced glycation end products (RAGE), in the inflammatory epidermis (9). However, the roles of S100A7 in other biological/pathological contexts, including its effects on tumor cells, remain unclear.

In the present study, we investigated the effects of S100A7 on the migration and invasion of osteosarcoma cells.

Materials and methods

Cell culture

The human osteosarcoma cell line Saos-2 (11) and the human breast cancer cell line MCF-7 (12) were obtained from the American Type Culture Collection (Rockville, MD, USA). The normal human fibroblast cell line OUMS-24 (13) and the human osteosarcoma cell line HuO9 (14) were established in our department. Saos-2, MCF-7 and HuO9 were cultured in RPMI-1640 (Invitrogen, Carlsbad, CA, USA). OUMS-24 was maintained in Dulbecco's modified EM (Nissui, Tokyo, Japan). All the media were supplemented with 10% FBS (Invitrogen), 100 μg/ml kanamycin (Meiji Seika, Tokyo, Japan) and 0.5 μg/ml Fungizone (Invitrogen). Primary normal human keratinocytes (NHK) were purchased from Kurabo (Osaka, Japan) and were cultured in HuMedia-KB2 (Kurabo) with Human Keratinocyte Growth Supplement (Invitrogen). To determine the effect of S100A7 on cell growth, Saos-2 cells were inoculated at 1×10⁵ cells/well and cultured in a serum-free medium containing indicated recombinant proteins (1 μg/ml). The 10% FBS-containing medium was used as a positive control.

Preparation of recombinant proteins

S100A7 (NM002963) cDNA was amplified by PCR and cloned into pGEX6P1 (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). The nucleotide sequence of the cDNA was confirmed by DNA sequencing. Escherichia coli (BL21) cells were transformed by the vector and the recombinant GST-fusion protein was purified by glutathione-agarose affinity chromatography using a Sepharose 4B column (GE Healthcare Bio-Sciences) under conventional conditions. GST was released by cleaving with PreScission protease (GE Healthcare Bio-Sciences) and removed from the final preparations using the Sepharose 4B column. Recombinant GST protein was also prepared and used as a negative control.

Pull-down assay and western blot analysis

Biotinylated recombinant S100A7 or GST protein (5 μg) was incubated with 5 μg of human RAGE Fc (R&D Systems, Minneapolis, MN, USA) and the complex of proteins was pulled down using streptavidine agarose (Invitrogen). After washing the agarose beads, the bound proteins were eluted and fractionated by SDS-PAGE. Streptavidine-HRP (R&D Systems) was used to detect the applied biotinylated S100A7 and GST proteins. Bound RAGE protein was detected by western blotting. Western blot analysis was performed under conventional conditions using 10 μg of protein extracts (15). The antibodies used were as follows: mouse anti-RAGE antibody (R&D Systems), mouse anti-tubulin antibody (Sigma, St. Louis, MO, USA) and HRP-linked anti-mouse IgG (Cell Signaling Technologies, Beverly, MA, USA).

RNA interference

siRNA against human RAGE (siGENOME SMART pool siRNA targeting AGER, Thermo Scientific Dharmacon, Lafayette, CO, USA) was transfected into cells using RNAi MAX reagent (Invitrogen). A control siRNA with no known mammalian homology (siGENONE non-targeting siRNA 1, Thermo Scientific Darmacon) was used as a negative control. The cells were incubated for 72 h and used for various assays.

Transmigration assay and invasion assay

The transmigration and invasion potentials of the cells were assayed in vitro under conditions similar to those described previously (16). Briefly, 50,000 osteosarcoma cells were inoculated into top wells of pre-coated Boyden chambers (pore size, 8 μm; BD Biosciences, Bedford, MA, USA). Following incubation, the filters were stained and the cells on the bottom surface were counted. For the transmigration assay, the chambers were coated with 2 μg of human fibronectin (Sigma) on the bottom and the incubation time was 8 h. For the invasion assay, 2 μg of human fibronectin and 10 μg of Matrigel (BD Biosciences) were applied onto the upper and lower sides, respectively, and the cells were incubated for 24 h. Mean values were obtained from 10 visual fields.

Gelatin zymography

Saos-2 cells were treated with siRNA for 24 h, washed twice and incubated with 10 ml of Opti-MEM (Invitrogen) supplemented with either S100A7 or GST. The conditioned medium was collected and concentrated into 100 μl by centrifugation using a Centricon (Amicon Ultra-15 Ultracell-10k; Millipore, Billerica, MA, USA) and then mixed with 50 μl of 3X SDS sample buffer. The samples (10 μl) were applied onto an 8% SDS-polyacrylamide slab gel containing 0.5% gelatin (Sigma). Following electrophoresis, the gel was washed with water to remove the SDS, soaked in protein refolding buffer (2.5% Triton X-100, 10% glycerol, 0.5 mM CaCl₂, 100 mM NaCl, 50 mM Tris-HCl/pH 7.4) for 1 h and incubated in 50 mM Tris-HCl/pH 7.4 containing 0.5 mM CaCl₂ for 12 h at 37°C. The gel was then stained with 1% Coomassie brilliant blue (CBB) and further treated with 10% methanol and 5% acetic acid to destain it. The gelatinolytic activity was detected as clear bands on a blue background of the CBB-stained gel. The recombinant matrix metalloproteinase (MMP)-2 and -9 proteins (R&D Systems) were used as positive controls.

Statistical analysis

Each experiment was repeated a minimum of three times. The results are expressed as the mean ± SD. The Student's t-test was used to compare the two groups. P<0.05 was considered to indicate a statistically significant result.

Results and Discussion

S100A7 promoted the migration of Saos-2 cells

We screened for S100 proteins that promote the migration of osteosarcoma cells. The cDNA of 20 S100 family members was cloned and GST-fused recombinant proteins were prepared. The proteins were applied to Saos-2 cells in the wound migration assay in vitro. Among the member proteins, S100A7 was identified as the most promising candidate (data not shown).

We confirmed the function of S100A7 in Saos-2 cells by the transmigration assay (Fig. 1). The number of cells that migrated was significantly increased by the S100A7 protein and the extent of the increase was dose-dependent. However, the growth of the Saos-2 cells was not affected by the addition of S100A7 protein (Fig. 2).

Figure 1.

S100A7 promoted the migration of Saos-2 cells as assessed by a transmigration assay. Saos-2 cells (50,000/well) were seeded into a Boyden chamber with purified recombinant proteins and cells that migrated were counted after 24 h. ^*P<0.05.

Figure 2.

Effect of S100A7 on cell growth of Saos-2 osteosarcoma. Saos-2 cells were cultured in a serum-free medium containing 10% FBS or 1 μg/ml recombinant proteins (GST or S100A7).

RAGE was necessary in S100A7-dependent promotion of Saos-2 cell migration

S100 proteins are recognized as damage-associated molecular pattern proteins (DAMPs) due to their release from damaged cells under conditions of cell stress (17). Certain DAMPs, including S100 proteins, are thought to be ligands for the multiligand receptor RAGE. RAGE is a type I transmembrane protein belonging to the immunoglobulin superfamily (18) and is involved in a broad range of inflammatory, degenerative and hyperproliferative diseases, including sepsis, rheumatoid arthritis, diabetic nephropathy/angiopathy, atherosclerosis, cancer and neurological disorders (19,20). The receptor is composed of an extracellular region, a hydrophobic transmembrane-spanning domain and a short cytoplasmic tail. The extracellular domain binds a number of ligands, including advanced glycation end products, high-mobility group box 1, S100 family proteins and amyloid fibrils (21). Wolf et al (9) revealed the interaction between S100A7 and RAGE by a competitive ligand binding assay. We performed a pull-down assay using recombinant RAGE and biotinylated S100A7 proteins (Fig. 3A). The RAGE protein was co-precipitated with biotinylated GST-S100A7 but not with biotinylated GST. The measurement of the surface plasmon resonance of these proteins also supported their interaction (data not shown). RAGE is expressed in various types of human cancer, including brain, breast, colon, lung, oral squamous cell and ovarian cancer (22). The expression of RAGE was examined in osteosarcoma cell lines, and the results showed that compared with normal fibroblasts and keratinocytes, which are known to express RAGE protein, osteosarcoma cells (Saos-2 and HuO9) expressed RAGE protein at high levels (Fig. 3B).

Figure 3.

Direct binding of S100A7 with RAGE. (A) A pull-down assay using recombinant proteins. Biotinylated GST or GST-S100A7 (5 μg) was incubated with human RAGE Fc, pulled down using streptavidin-agarose and eluted. Left panel: GST and GST-S100A7 were visualized using streptabidine-HRP. Right panel: RAGE protein that co-precipitated with GST-S100A7 was detected by anti-RAGE antibody. (B) Expression of RAGE in normal fibroblasts (OUMS-24), normal human keratinocytes (NHK), breast cancer cells (MCF-7) and osteosarcoma cells (Saos-2 and HuO9) as demonstrated by western blot analysis.

The functional involvement of RAGE in the S100A7-induced promotion of migration of osteosarcoma cells was also assessed. The expression of RAGE was successfully downregulated by the specific siRNA in Saos-2 cells (Fig. 4A). The downregulation of RAGE resulted in marked eradication of the S100A7-promoted transmigration of Saos-2 cells (Fig. 4B). Notably, RAGE downregulation suppressed not only the migration of S100A7-stimulated Saos-2 cells but also that of unstimulated cells, suggesting a potential role of endogenous S100A7 and/or other RAGE ligands in transmigration capacity.

Figure 4.

Inhibition of the migration of Saos-2 cells by the downregulation of RAGE. (A) Extracts were analyzed by western blotting 72 h after the application of 150 pmol RAGE siRNA to Saos-2 cells. (B) Cells in which RAGE was downregulated were used for a 24-h transmigration assay. ^*P<0.05.

S100A7 promoted the invasion and MMP activity of osteosarcoma cells

The coordination of cell migration and the degradation of matrix proteins is crucial for the invasion of malignant cells. We therefore performed an invasion assay that mimicks the invasion of cancer cells passing through the basement membrane (23). The addition of S100A7 significantly increased the invasion capacity of Saos-2 and HuO9 osteosarcoma cells (Fig. 5A). The downregulation of RAGE by siRNA demonstrates that the invasion of Saos-2 cells also depends on the expression of RAGE (Fig. 5B).

Figure 5.

Effect of S100A7 protein on the invasion of osteosarcoma cells. (A) Enhanced invasion of Saos-2 and HuO9 cells by S100A7. The experiment was performed under conditions similar to those in Fig. 1, with the exception of coating the upper side of the membrane with Matrigel. The concentration of the proteins was 1 μg/ml. ^*P<0.05 (B) Downregulation of RAGE inhibited the invasion of Saos-2 cells as assayed in the presence of 1 μg/ml S100A7. siRNA was applied to the cells under conditions similar to those in Fig. 3. ^*P<0.05 (C) Gelatin zymography of Saos-2 cells, which were processed under conditions identical to those in (B). The cells were subjected to gelatin zymography 24 h after incubation with purified recombinant proteins in the serum-free medium.

MMPs are known to be involved in the invasion of various types of cancer cells, including osteosarcoma cells (24,25). We analyzed the activity of MMPs by gelatin zymography (Fig. 5C). The application of S100A7 to Saos-2 cells resulted in a marked enhancement of the activity of MMP-2 and MMP-9 (Fig. 5C). Collectively, our results indicate that the S100A7-RAGE signal transdution pathway is involved in the invasion of osteosarcoma cells.

S100A7 is known to promote breast cancer progression (26). However, S100A7 has been reported to act as a negative regulator of breast cancer invasion (27). Our data have demonstrated that S100A7 promoted the migration and invasion of osteosarcoma cells in vitro. A crucial question is whether S100A7 functions to promote the invasion and/or metastasis of osteosarcoma in vivo. Hiratsuka et al (28) revealed that S100A8 and S100A9 indirectly act on the lung to accelerate the migration of primary tumor cells to lung tissues. Andresen et al (29) reported that the expression of S100A7 was detected in the normal lung and that it was increased under pathological conditions. An increased production of S100A7 in the lung may enable circulating cancer cells to settle and grow invasively in the lung. Although further studies are needed, the S100A7-RAGE axis may be a new target for preventing the invasion and/or metastasis of osteosarcoma.

Abbreviations

RAGE

receptor for advanced glycation end products

siRNA

small interfering RNA

CBB

Coomassie brilliant blue

MMP

matrix metalloproteinase